CCL5 and thanatophoric dysplasia: Given the nature of recurring of TDs, pharmaceutical lowering of the level of blood CCL5, attenuation of expression or function of CCR1/5, or inhibition of CCL5-CCR1/5 or CCL5-heparan sulfates interactions, such as by CCL5 antagonist, monoclonal antibodies to CCR1/5, or heparan sulfates competitive inhibitor heparin (37), would hold promise for better risk management of TD relapse.